EMILY ENCE: Open Payments
NPI 1063784478 · LA JOLLA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$773 in 34 payments from 12 companies in 2025. Trend: 2023 $963 · 2024 $1,544 · 2025 $773
Food & beverage: $773
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 13 | $234 |
| Phadia US Inc. | 1 | $94 |
| Hologic Sales and Service, LLC | 3 | $76 |
| Lilly USA, LLC | 3 | $58 |
| SANOFI PASTEUR INC. | 3 | $56 |
| AstraZeneca Pharmaceuticals LP | 3 | $52 |
| GlaxoSmithKline, LLC. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| GENZYME CORPORATION | 1 | $36 |
| Verity Pharmaceuticals Inc. | 1 | $33 |
Products named: ImmunoCAP, APTIMA, MOUNJARO, BREZTRI, SHINGRIX, CAPLYTA, DUPIXENT, Tlando.
Industry payments across CA — which companies pay providers there.
